R & D daily to develop hair loss innovative therapy Erjian has reached R & D cooperation

Jardiance is better than DPP-4 inhibitor and GLP-1 receptor agonist in reducing the risk of heart failure in Hospital; Sansheng pharmaceutical is authorized by PSGL-1 monoclonal antibody, a new target of immunotherapy; Erjian has achieved R & D cooperation in the development of hair loss innovative therapy; yushbi il17-a / F double inhibitor has reached the end of phase 3 again We focus on the latest development of pharmaceutical research and development, and provide timely and accurate information reference for R & D personnel The latest analysis of the three-year data of emprise (nct03363464), a large-scale real world study, was released at the 2019 annual scientific conference of the American Heart Association held in Philadelphia recently The results showed that compared with DPP-4 inhibitors and GLP-1 receptor agonists, jardiance (empagliflozin, engeliejin) was associated with reduced hospitalization risk of heart failure There is a similar risk of nonfatal atherosclerotic cardiovascular events Recently, youshibi, a pharmaceutical company based in Brussels, Belgium, announced that bimekizumab, an IL-17A / F monoclonal antibody under development for the treatment of chronic moderate to severe plaque psoriasis, had reached two common primary endpoints and all secondary endpoints in the key phase 3 trials It is expected that in mid-2020, youshibi will submit regulatory applications for bimekizumab Sansheng pharmaceutical and Verseau therapeutics, Inc today announced that according to the cooperation agreement between the two sides on the research and development and commercialization of innovative monoclonal antibodies for multiple cancers, they have selected vtx-0811, a monoclonal antibody targeted at PSGL-1, as the first licensed product Recently, amarin announced that the FDA's endocrine and Metabolic Drug Advisory Committee approved the results by a vote, supporting the company's vascepa (icosapent ethyl) capsule as a new therapy to reduce the risk of adverse cardiovascular events The FDA is expected to respond to the drug's new drug supplement application on December 28 this year On November 18, Redhill biopharma (Redhill) announced that its antibiotic talicia was approved by the FDA for use in the treatment of adult patients with Helicobacter pylori infection, so as to reduce the risk of gastric cancer caused by Helicobacter pylori and solve the problem of antibiotic resistance of the bacteria , A few days ago, Johnson & Johnson Group's Yang Sen company announced that it will launch the first full "virtual" clinical trial, using personal smart phones and wearable devices to track patients Patients participating in the clinical trial do not need to go to the clinical trial site in person for examination The clinical trial, called chief-ihf, aims to gather real-world evidence to support the company's new indications in the cardiovascular field of SGLT2 inhibitor canagliflozin Recently, exicure announced that it has signed a global cooperation agreement with Elgin The two companies will develop two new treatments for hair loss by using the unique 3D spherical nucleic acid platform technology of exicure.